FDA clinical hold review committee
Will convene for its second meeting in late March, FDA announces in the Feb. 28 Federal Register. Composed of senior agency officials, the committee was created last October as part of an experimental procedure for reviewing clinical holds placed by the agency on experimental drug products. Products on clinical hold are selected for committee review by FDA Ombudsman Amanda Pedersen, who picks some at random through the Center for Drug Evaluation & Research's management information system and some from requests by sponsors. All meetings are closed due to the confidential information being discussed. Companies that would like the committee, at its March meeting, to take up products placed on clinical hold during FY 1991-1992 are requested to contact FDA by March 16.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth